Topic resource collection
Approved comparison material connected to this topic.
7 resourcesRead both sides
Selank GABAergic modulation, monoamine metabolism 4 RCTs (n=312 total) 0.15% solution, 3 drops per nostril 2× daily Intranasal Modest evidence for short-term anxiety reduction. Effect size is clinically detectable but not transfo…
Here's the honest answer: most published studies comparing peptides for anxiety research use fundamentally flawed experimental designs. They test Selank, Semax, and P21 in the same behavioral assay. Typically elevated plus maze o…
When researchers compare peptides for anxiety research, the first fork in the decision tree is mechanism class. Selank operates primarily through GABAergic tone modulation. It enhances GABA metabolism without binding GABA recepto…
Before selecting a peptide for anxiety research protocols, understanding the mechanistic, temporal, and logistical differences across compounds is essential. The following table compares the three most studied peptides in anxiety…
A key research distinction of Selank from classical GABAergic anxiolytics (benzodiazepines) is the combination of: GABA-A positive modulation (anxiety reduction) + BDNF neuroplasticity enhancement (antidepressant and neuroprotect…
The table below compares intranasal vs subcutaneous anxiolytic peptide protocols based on administration complexity, onset time, and dosing precision requirements. Selank Intranasal 300–900 mcg/day 15–30 minutes No (pre-mixed) Fa…
Selank GABA-A receptor upregulation Panic disorder, acute episodic anxiety 600mcg–2.4mg/day intranasal or subcutaneous 10–14 days Multiple RCTs, moderate-quality evidence Semax BDNF elevation, neuroprotection GAD, chronic stress-…